This is a patient wearing MemorEM. CREDIT NeuroEM Therapeutics, Inc.
Alzheimer’s Disease (AD) is disease of brain aging that causes progressive, severe memory loss. There is no effective “drug” to prevent or treat AD and most believe that it is unlikely that any will be developed in the near future. Therefore, other therapeutic interventions are desperately needed.
NeuroEM Therapeutics has developed a first-in-class, self-contained head device (the MemorEM™) to treat AD with electromagnetic waves – a therapy that they have pioneered and tested successfully in AD animal studies with no adverse events seen. Our novel, proprietary technology appears to directly affect the AD process to prevent and reverse memory impairment. The MemorEM head device, which allows for complete mobility during one-hour treatments “in home”, has been successfully used in NeuroEM’s just-completed Open-Label clinical trial that evaluated the safety and efficacy of Transcranial Electromagnetic Treatment (TEMT) in Alzheimer’s patients. In view of its promising effects on memory in this clinical trial, TEMT could be an entirely new bioengineering-based intervention against AD.
The investigators had previously demonstrated that treating AD mice with electromagnetic waves in the radiofrequency range resulted in protection against memory impairment in young AD mice and reversal of memory impairment in aged AD mice.
For the present clinical study in humans, the investigators used the same treatment (twice daily for 1-hour) through creation of NeuroEM’s first-in-class MemorEMTM head device. The device has multiple, highly-specialized emitters positioned within a head cap that are activated sequentially, with treatments easily administered in-home by the patient’s caregiver. As well, the device allows for near complete mobility to perform nearly all household activities during treatments.
Results demonstrate that TEMT was safe in all eight participating patients with mild to moderate AD and enhanced cognitive performance in seven of them, as measured by their ADAS-cog score, which is the benchmark for testing AD therapeutics.
The investigators indicated they have strong evidence that TEMT is directly affecting the Alzheimer’s disease process by easily penetrating the brain and brain cells to break up aggregates of two toxic proteins inside brain cells called A-beta and tau.
TEMT’s ability to disaggregate both toxic proteins inside brain cells (neurons) appears to be key to stopping and reversing the cognitive loss of AD. Present AD drugs in clinical trials have great difficulty getting into the brain and then into brain cells. Even if they succeeded in doing so, they do not yet have the capacity to target the small aggregates of A-beta and tau proteins that appear to be causative to AD.
NeuroEM Therapeutics is planning for a pivotal clinical trial to begin recruitment of approximately 150 mild/moderate AD subjects later this year for treatment with the company’s MemorEMTM device. If that trial shows continued safety and cognitive benefits, NeuroEM Therapeutics plans to ask the FDA for approval of the MemorEM device for treatment of AD. The clinical locations for this multi-site trial have not yet been determined.
Journal of Alzheimer’s Disease – A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging